P53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway

Cell Death and Differentiation

Volumn 20, Issue 7, 2013, Pages 888-897

  Farhang Ghahremani, M ^a,b   Goossens, S ^a,b   Nittner, D ^c,d   Bisteau, X ^e   Bartunkova, S ^a,b   Zwolinska, A ^c,d   Hulpiau, P ^a,b   Haigh, K ^a,b   Haenebalcke, L ^a,b   Drogat, B ^a,b,e   Jochemsen, A ^f   Roger, P P ^e   Marine, J C ^c,d   Haigh, J J ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; p21; p53; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL CYCLE REGULATION; CELL HYPOXIA; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; XENOTRANSPLANTATION;

ANIMALS; ANOXIA; BASE SEQUENCE; CELL LINE, TUMOR; CELLS, CULTURED; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FIBROBLASTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880321397     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.12     Document Type: Article

References (46)

1. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
2. Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition - a critical review. Anticancer Agents Med Chem 2007; 7: 223-245.
3. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-1225.
4. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071-1121.
5. Liu W, Xu J, Wang M, Wang Q, Bi Y, Han M. Tumor-derived vascular endothelial growth factor (VEGF) - a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int J Oncol 2011; 39: 1213-1220.
6. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15: 167-170.
7. Beck B, Driessens G, Goossens S, Youssef KK, Kuchnio A, Caauwe A et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011; 478: 399-403.
8. Sermeus A, Michiels C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2011; 2: e164.
9. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev 2002; 2: 594-604.
10. Agani F, Kirsch DG, Friedman SL, Kastan MB, Semenza GL. P53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. Cancer Res 1997; 57: 4474-4477.
11. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995; 55: 6161-6165.
12. Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 2001; 61: 6952-6957.
13. Qin G, Kishore R, Dolan CM, Silver M, Wecker A, Luedemann CN et al. Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF. Proc Natl Acad Sci USA 2006; 103: 11015-11020.
14. Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 2000; 60: 3655-3661.
15. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 2006; 66: 6264-6270.
16. An WGKM, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. Stabilization of wildtype p53 by hypoxia-inducible factor 1alpha. Nature 1998; 392: 405-408.
17. Chen D, Li M, Luo J, Gu W. Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem 2003; 278: 13595-13598.
18. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000; 14: 34-44.
19. Nieminen AL, Qanungo S, Schneider EA, Jiang BH, Agani FH. Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia. J Cell Physiol 2005; 204: 364-369.
20. Fukasawa M, Tsuchiya T, Takayama E, Shinomiya N, Uyeda K, Sakakibara R et al. Identification and characterization of the hypoxia-responsive element of the human placental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene. J Biochem 2004; 136: 273-277.
21. Kurz EU, Douglas P, Lees-Miller SP. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 2004; 279: 53272-53281.
22. Graeber TGPJ, Tsai M, Monica K, Fornace AJ, Giaccia AJ. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994; 14: 6264-6277.
23. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G et al. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 2006; 103: 3232-3237.
24. Hooghe B, Hulpiau P, van Roy F, De Bleser P. ConTra: a promoter alignment analysis tool for identification of transcription factor binding sites across species. Nucleic Acids Res 2008; 36: W128-W132.
25. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613.
26. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 2010; 107: 6334-6339.
27. Dimri GP, Nakanishi M, Desprez PY, Smith JR, Campisi J. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol 1996; 16: 2987-2997.
28. Gurley LR, D'Anna JA, Barham SS, Deaven LL, Tobey RA. Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem 1978; 84: 1-15.
29. Nowak SJ, Corces VG. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet 2004; 20: 214-220.
30. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010; 17: 135-147.
31. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-322.
32. Schroy PC 3rd, Brown-Shimer S, Kim K, Johnson KA, Murnane MJ, Yang S et al. Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay. Cancer 1995; 76: 201-209.
33. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444: 61-66.
34. Green AL, Meek ES, White DW, Stevens RH, Ackerman LD, Judisch GF et al. Retinoblastoma Y79 cell line: a study of membrane structures. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1979; 211: 279-287.
35. Campbell M, Chader GJ. Retinoblastoma cells in tissue culture. Ophthalmic Paediatr Genet 1988; 9: 171-199.
36. Pereira ER, Liao N, Neale GA, Hendershot LM. Transcriptional and post-transcriptional regulation of proangiogenic factors by the unfolded protein response. PLoS One 2010; 5, pii e12521.
37. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001; 61: 6234-6238.
38. Fortunato P, Pillozzi S, Tamburini A, Pollazzi L, Franchi A, La Torre A et al. Irresponsiveness of two retinoblastoma cases to conservative therapy correlates with up-regulation of hERG1 channels and of the VEGF-A pathway. BMC Cancer 2010; 10: 504.
39. Yang H, Cheng R, Liu G, Zhong Q, Li C, Cai W et al. PEDF inhibits growth of retinoblastoma by anti-angiogenic activity. Cancer Sci 2009; 100: 2419-2425.
40. Maxwell PH. Hypoxia-inducible factor as a physiological regulator. Exp Physiol 2005; 90: 791-797.
41. Maddocks OD, Vousden KH. Metabolic regulation by p53. J Mol Med (Berl) 2011; 89: 237-245.
42. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005; 201: 1089-1099.
43. Migliorini D, Lazzerini Denchi E, Danovi D, Jochemsen A, Capillo M, Gobbi A et al. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 2002; 22: 5527-5538.
44. Ohkubo S, Tanaka T, Taya Y, Kitazato K, Prives C. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. J Biol Chem 2006; 281: 16943-16950.
45. Peitz M, Pfannkuche K, Rajewsky K, Edenhofer F. Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes. Proc Natl Acad Sci USA 2002; 99: 4489-4494.
46. Broos S, Hulpiau P, Galle J, Hooghe B, Van Roy F, De Bleser P. ConTra v2: a tool to identify transcription factor binding sites across species, update 2011.. Nucleic Acids Res 2011; 39: W74-78.